Navigation Links
Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 46th American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

., S Hall A2
  • Poster session: Lymphoma and Plasma Cell Disorders
  • Abstract #8135, poster board 37E

  • Solid Tumors & Multiple Myeloma

    Updated Results of a Phase 1b/2 Study of Carfilzomib in Patients with Relapsed Malignancies

    • Dr. Peter Lee, Tower Cancer Research Foundation
    • Saturday, June 5, 2010, 8:00 a.m. - 12:00 p.m., S Hall A2
    • Poster session: Lymphoma and Plasma Cell Disorders
    • Abstract #8147, poster board 39A

    About the Carfilzomib Development Program

    Carfilzomib is a selective, next generation proteasome inhibitor that has shown encouraging results in a broad clinical trial program in multiple myeloma.

    In addition, the company intends to initiate a large, randomized international Phase 3 clinical trial, known as the 009 trial, this year to study the combination of lenalidomide and low dose dexamethasone with or without carfilzomib in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMEA) on the design and planned analysis of the 009 trial. A second Phase 3 clinical trial, the 011 trial, of carfilzomib in relapsed and refractory myeloma is planned in Europe. Carfilzomib is also being evaluated in advanced solid tumors.

    About Multiple Myeloma

    Multiple myeloma (MM) is the second most common hematologic cancer and results from an abnormality of plasma cells, usually
    '/>"/>

    SOURCE Onyx Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... , Sept. 18, 2014  ADM Tronics Unlimited, ... , Ph.D. to its corporate Advisory Board for ... instructor at the Harvard Medical School and Visiting ... He received his Masters degree in Electronics Engineering ... from the University of Bologna. After spending a year ...
    (Date:9/18/2014)... Sept. 18, 2014  A $3 million grant from ... University of Michigan to establish a national center of ... Center for Aging Research at U-M will focus on ... slow the effects of aging and postpone diseases in ... that can help develop medications that may help people ...
    (Date:9/18/2014)...  Neurotrope, Inc. (OTCQB: NTRP) today announced the appointment ... the Company,s Board of Directors, effective September 12, 2014. ... the Board of seven members. Dr. Altstiel will also ... and a member of the Audit and Compensation Committees ... Scientific Advisory Board, a position he has held since ...
    Breaking Medicine Technology:ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 2Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 4
    ... 20, 2011 Reportlinker.com announces that a new ... Rheumatoid Arthritis Market Forecast ... launch of novel oral drugs and reformulations of ... the seven major markets, rising from $12bn in ...
    ... Sept. 20, 2011 Reportlinker.com announces ... is available in its catalogue: ... Therapy (HRT) - Pipeline Assessment and ... http://www.reportlinker.com/p0617091/Post-Menopausal-Hormone-Replacement-Therapy-HRT---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy ...
    Cached Medicine Technology:Rheumatoid Arthritis Market Forecast 2Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 2Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 3Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 4Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 5Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 6Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 7Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 8Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018 9
    (Date:9/18/2014)... San Luis Obispo, CA (PRWEB) September 18, 2014 ... Bunion Bootie introduced their newest, patent pending bunion splint ... , As one loyalist, Rosa, wrote: "I was absolutely delighted. ... comfortable... I honestly forget I am wearing them. THANK YOU ... the recently introduced design by saying, "The hole used to ...
    (Date:9/18/2014)... It is that time of year – time ... again, Evensong Spa at Heidel House Resort ... at a special $50 rate Oct. 20 through Nov. 1. ... & Resorts , is the only Wisconsin destination spa participating ... health and wellness by experiencing affordable spa and wellness treatments. ...
    (Date:9/18/2014)... (HealthDay News) -- Daily supplements of selenium or vitamin ... of age-related cataracts among men, a new study indicates. ... both could help prevent cataracts. To investigate this further, ... Medical School in Boston, and his colleagues examined data ... E. The trial was initially designed to study prevention ...
    (Date:9/18/2014)... 19, 2014 In 2003, ... Mission (Misión Barrio Adentro), which it hoped ... system (see Section 6.1.3.). In 2009, it ... Autonomous Service of Pharmaceutical Elaborations (Servicio Autónomo ... provides medicines at a cheaper rate than ...
    (Date:9/18/2014)... Qualis Health, one of the nation’s leading population ... “Advancing Primary Care through the Patient-Centered Medical Home Model ... Jeff Hummel, MD, MPH and Peggy C. Evans, PhD, ... the work of becoming a Patient-Centered Medical Home (PCMH) ... such as generating and providing useful data that can ...
    Breaking Medicine News(10 mins):Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2
    ... ... Learning, is happy to announce the release of their new title in the Tarascon ... Dacso, MD, MSc. This convenient, portable guide provides regional and issue-based information on ... ...
    ... sense of family discord implicated in new study , ... and psychology may be the cause of attention-deficit hyperactivity disorder ... found that ADHD symptoms were more common in children and ... serotonin and who blame themselves for conflict between their parents. ...
    ... "We ... the easy to use workflow currently enjoyed by HyperSign subscribers and allow them to ... ... a S.C.- based technology development company announced today that its award winning digital signage ...
    ... the University of Alabama at Birmingham (UAB) Department of ... will help predict which patients are more likely to ... findings also shed light on the genetics that result ... Caucasians, the researchers said. In data presented April ...
    ... ... selling their premium brand electronic cigarettes via the internet. , ... Reno, NV (PRWEB) April 18, 2010 -- ... electronic cigarettes via the internet. Previously, Freedom was sold exclusively through retail outlets. ...
    ... ... fire sprinklers had been installed in these homes, many of these lives would have been saved. ... these live-safety systems in homes are well trained and accredited. , ... Whittier, CA (PRWEB) April 19, 2010 -- More than 3,000 people in ...
    Cached Medicine News:Health News:Tarascon Announces New Title In Their Pocketbook Series: Global Health 2Health News:Tarascon Announces New Title In Their Pocketbook Series: Global Health 3Health News:Award Winning HyperSign Digital Signage Service Now Includes Interactive Signage 2Health News:UAB researchers find 4 biomarkers important in colerectal cancer treatment prognosis 2Health News:Freedom Smokeless Electronic Cigarette Sales Are Smoke ‘N 2Health News:Partnering to Enhance Consumer Safety with Residential Fire Sprinklers 2Health News:Partnering to Enhance Consumer Safety with Residential Fire Sprinklers 3
    ... Tecoflex stents that save inventory, shelf space, ... ureteral lengths from 22 cm to 28 ... Quadra-Coil to glide over any guidewire and ... provide ease of placement and patient comfort ...
    ... for temporary internal drainage from the ... sterile in peel-open packages. Intended for ... advised; C-Flex® and Sof-Flex® stents must ... (6) months; silicone stents must not ...
    ... Classic Double Pigtail Ureteral Stents have ... that maximizes migration. They also feature ... and cost savings. Each Classic ... one Classic Double PigTail Ureteral Stent ...
    ... internal drainage from the ureteropelvic ... filiform stent assembly provides one ... peel-open packages. Intended for one-time ... advised; stent must not remain ...
    Medicine Products: